{ "company": "Natera", "ticker": "NTRA", "period": { "from": "2026-03-22", "to": "2026-04-21", "days": 30 }, "sentiment_breakdown": { "positive": 37, "negative": 37, "neutral": 34 }, "synthesis": { "executive_summary": "Sentiment analysis for Natera (NTRA) from 2026-03-22 to 2026-04-21. Analyzed 108 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "date": "2026-04-08", "source": "alpha_vantage", "score": 0.812 }, { "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "date": "2026-04-07", "source": "alpha_vantage", "score": 0.812 }, { "title": "Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib", "date": "2026-04-17", "source": "news", "score": 0.772 }, { "title": "Natera Inc stock (US6323071042): Is cell-free DNA testing strong enough to unlock sustained growth?", "date": "2026-04-14", "source": "alpha_vantage", "score": 0.71 }, { "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth", "date": "2026-03-27", "source": "news", "score": 0.637 }, { "title": "Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA)", "date": "2026-04-10", "source": "alpha_vantage", "score": 0.586 }, { "title": "William Blair initiates Natera stock with Outperform on growth outlook", "date": "2026-04-13", "source": "alpha_vantage", "score": 0.582 }, { "title": "Angels George Klassen's inspiring journey back from head injury to MLB debut", "date": "2026-04-11", "source": "news", "score": 0.572 }, { "title": "Natera wins 30% ongoing royalty in patent case against Invitae By Investing.com", "date": "2026-04-09", "source": "alpha_vantage", "score": 0.572 }, { "title": "56,665 Shares in Natera, Inc. $NTRA Purchased by Robinhood Asset Management LLC", "date": "2026-04-07", "source": "alpha_vantage", "score": 0.572 } ], "top_negative": [ { "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -1.0 }, { "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "date": "2026-03-27", "source": "news", "score": -0.945 }, { "title": "ASO Author Reflections: Potential of Circulating Tumor DNA in Stratifying Patients with Localized pMMR Colon Cancer to Neoadjuvant Therapy.", "date": "2026 Apr 1", "source": "pubmed", "score": -0.791 }, { "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.", "date": "2026 Apr 9", "source": "pubmed", "score": -0.758 }, { "title": "Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies.", "date": "2026 Apr 1", "source": "pubmed", "score": -0.694 }, { "title": "Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model.", "date": "2026-04-21", "source": "pubmed", "score": -0.691 }, { "title": "Signatera Data in Older Breast Cancer Patients Could Be A Game Changer For Natera (NTRA)", "date": "2026-04-01", "source": "alpha_vantage", "score": -0.66 }, { "title": "Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery", "date": "2026-03-31", "source": "alpha_vantage", "score": -0.66 }, { "title": "Targeting genomic instability in cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -0.66 }, { "title": "In vivo exposure to CXCL12-high CAFs and chronic CXCL12 stimulation in vitro is sufficient to enhance metastasis of ER-positive breast cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -0.66 } ], "raw_data": { "total_items": 108, "items": [ { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-04-01", "url": "https://www.sec.gov/Archives/edgar/data/1604821/000110465926038519/0001104659-26-038519-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib", "description": "Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR...", "url": "https://www.globenewswire.com/news-release/2026/04/17/3276007/35186/en/Kura-Oncology-Reports-Darlifarnib-Plus-Cabozantinib-Demonstrates-Robust-Activity-in-Patients-With-Clear-Cell-Renal-Cell-Carcinoma-Previously-Treated-With-Cabozantinib.html", "date": "2026-04-17", "published_at": "2026-04-17T10:00:00Z", "sentiment": { "label": "positive", "score": 0.772, "confidence": 0.77 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "American Kidney Fund Announces 2026 Class of Corporate Members Supporting Work to Fight Kidney Disease", "description": "ROCKVILLE, Md., April 13, 2026 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) announced today its 2026 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program. Corporate Members support AKF in fighting kidney disea…", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272711/0/en/American-Kidney-Fund-Announces-2026-Class-of-Corporate-Members-Supporting-Work-to-Fight-Kidney-Disease.html", "date": "2026-04-13", "published_at": "2026-04-13T15:37:00Z", "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "news", "source_name": "USA Today", "title": "Angels George Klassen's inspiring journey back from head injury to MLB debut", "description": "About a year ago, the Angels No. 3 prospect George Klassen was in the hospital. Now, he's getting ready to make his second big league start Saturday.", "url": "https://www.usatoday.com/story/sports/mlb/angels/2026/04/11/george-klassen-los-angeles-angels-mental-hurdles-concussion/89565733007/", "date": "2026-04-11", "published_at": "2026-04-11T14:23:33Z", "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Rapid Growth in Cell-Free Tumor DNA Detection Market: Forecast to Reach $5.64 Billion by 2030 as Advancements in Personalized Medicine Propel Expansion", "description": "Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The \"Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Report 2026\" has been added to ResearchAndMarkets.com's offering.", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269503/28124/en/Rapid-Growth-in-Cell-Free-Tumor-DNA-Detection-Market-Forecast-to-Reach-5-64-Billion-by-2030-as-Advancements-in-Personalized-Medicine-Propel-Expansion.html", "date": "2026-04-07", "published_at": "2026-04-07T16:23:00Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html", "date": "2026-03-27", "published_at": "2026-03-27T16:31:00Z", "sentiment": { "label": "negative", "score": -0.945, "confidence": 0.95 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth", "description": "Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The \"Oncology Precision Medicine Market Report 2026\" has been added to ResearchAndMarkets.com's offering. ...", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263857/28124/en/Oncology-Precision-Medicine-Market-Trends-and-Investment-Opportunities-2026-2030-Advancements-in-CAR-T-and-Gene-Therapies-Propel-Precision-Oncology-Growth.html", "date": "2026-03-27", "published_at": "2026-03-27T14:44:00Z", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results", "description": "NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:", "url": "https://www.globenewswire.com/news-release/2026/03/26/3263407/0/en/IMDX-Submits-GraftAssureDx-for-FDA-Review-and-Reports-Q4-2025-Results.html", "date": "2026-03-26", "published_at": "2026-03-26T20:05:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "url": "https://www.tradingview.com/news/stockstory:b5f17f6f5094b:0-biotechnology-stocks-q3-results-benchmarking-natera-nasdaq-ntra/", "date": "2026-04-21", "summary": "This article analyzes the Q3 earnings of Natera (NTRA) and compares its performance to other biotechnology companies like Novavax (NVAX), United Therapeutics (UTHR), Regeneron (REGN), and AbbVie (ABBV). Natera reported strong Q3 results with revenues exceeding expectations, while Novavax showed the biggest analyst beat and fastest revenue growth. United Therapeutics, however, had the weakest performance against analyst estimates.", "sentiment_score": 0.454898, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know", "url": "https://uk.finance.yahoo.com/news/natera-ufp-technologies-mettler-toledo-125626885.html", "date": "2026-04-18", "summary": "Shares of Natera, UFP Technologies, Mettler-Toledo, and Viatris rose significantly following the reopening of the Strait of Hormuz, which signals a decrease in global logistics and energy costs. This will directly benefit healthcare providers and medical device manufacturers by reducing operating and shipping expenses, leading to a more favorable outlook on quarterly earnings. The \"risk-on\" sentiment from a ceasefire is also driving investment back into high-growth biotech and pharmaceutical com", "sentiment_score": 0.428571, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Cwm LLC Has $19 Million Holdings in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-cwm-llc-has-19-million-holdings-in-natera-inc-ntra-2026-04-18/", "date": "2026-04-18", "summary": "Cwm LLC significantly increased its stake in Natera, Inc. by 16.9% in the fourth quarter, bringing its total holdings to 82,933 shares valued at approximately $19.0 million. This increase occurred despite substantial insider selling activity, with several executives selling shares worth millions in recent months. Natera has shown strong financial performance, beating Q4 earnings and revenue estimates, and analysts maintain a \"Moderate Buy\" rating with a target price around $253.47.", "sentiment_score": 0.226273, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera, Inc. (NASDAQ:NTRA) Given Average Recommendation of \"Moderate Buy\" by Brokerages", "url": "https://www.marketbeat.com/instant-alerts/natera-inc-nasdaqntra-given-average-recommendation-of-moderate-buy-by-brokerages-2026-04-18/", "date": "2026-04-18", "summary": "MarketBeat reports that Natera, Inc. (NASDAQ:NTRA) has received a consensus \"Moderate Buy\" rating from nineteen research firms, with an average 12-month target price of $253.47. Despite strong institutional buying, company insiders have sold a significant number of shares, including CFO Michael Burkes Brophy. The company recently beat earnings expectations but still faces negative margins, with analysts projecting negative EPS for the current year.", "sentiment_score": 0.238089, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) Tops Q4 Earnings and Revenue Estimates", "url": "https://www.easternprogress.com/natera-ntra-tops-q4-earnings-and-revenue-estimates/article_b66957c5-478d-5d50-a67b-78c4a51947e2.html", "date": "2026-04-16", "summary": "Natera (NTRA) reported strong fourth-quarter results, surpassing Zacks Consensus Estimates for both earnings and revenue. The company posted earnings of $0.35 per share, significantly beating the estimated loss of $0.46, and revenues of $665.5 million, exceeding expectations by 0.76%. Despite this positive performance, Natera currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revision trends ahead of the earnings release.", "sentiment_score": 0.391278, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Natera, Inc. (NASDAQ:NTRA) Short Interest Up 47.2% in March", "url": "https://www.marketbeat.com/instant-alerts/natera-inc-nasdaqntra-short-interest-up-472-in-march-2026-04-14/", "date": "2026-04-15", "summary": "Natera, Inc. (NASDAQ:NTRA) experienced a 47.2% increase in short interest during March, reaching 4,867,085 shares. Despite this, the company's insiders sold a significant number of shares, while institutional investors hold nearly all of the stock. Natera also surpassed quarterly earnings and revenue estimates, leading analysts to issue a \"Moderate Buy\" rating with an average target price of $253.47.", "sentiment_score": 0.330396, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Is It Time To Reassess Natera (NTRA) After Its Mixed Share Price Performance?", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-it-time-to-reassess-natera-ntra-after-its-mixed-share-pri", "date": "2026-04-15", "summary": "This article evaluates Natera's (NTRA) share price performance using discounted cash flow (DCF) and price-to-sales (P/S) analyses. While the DCF model suggests the stock is undervalued by 31.0%, the P/S ratio indicates it is overvalued compared to its fair ratio. The article also presents \"Narratives\" from different analysts, outlining both bull and bear cases for Natera's future valuation and growth prospects.", "sentiment_score": 0.344327, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "William Blair initiates coverage of Natera (NTRA) with outperform recommendation", "url": "https://www.msn.com/en-us/money/top-stocks/william-blair-initiates-coverage-of-natera-ntra-with-outperform-recommendation/ar-AA20VjfX?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-04-14", "summary": "William Blair has initiated coverage of Natera (NTRA) with an \"outperform\" recommendation. This analyst rating suggests that William Blair expects Natera's stock to perform better than the broader market or its industry peers. The initiation of coverage by a prominent firm like William Blair could draw increased attention to Natera from investors.", "sentiment_score": 0.409649, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma", "url": "https://www.biospace.com/press-releases/natera-highlights-positive-interim-futility-analysis-from-allogene-therapeutics-mrd-guided-alpha3-trial-in-large-b-cell-lymphoma", "date": "2026-04-14", "summary": "Natera announced positive interim futility analysis from Allogene Therapeutics’ ALPHA3 trial for cema-cel, an investigational CAR T therapy for large B-cell lymphoma (LBCL). The study uses Natera's CLARITY™ MRD assay to identify high-risk patients, revealing that 58.3% of MRD-positive patients treated with cema-cel achieved MRD clearance and showed a significant reduction in plasma ctDNA levels compared to the observation arm. These results suggest cema-cel could prevent or delay relapse in LBCL", "sentiment_score": 0.470657, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "alpha_vantage", "title": "Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst", "url": "https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51815723/natera-positioned-to-capture-growing-20-billion-mrd-opportunity-analyst", "date": "2026-04-14", "summary": "William Blair initiated coverage on Natera (NASDAQ: NTRA), emphasizing the company's strong position in the growing minimal residual disease (MRD) testing market, estimated at over $20 billion. Analyst Andrew Brackmann projects Natera's MRD revenue, estimated at nearly $1 billion in 2025, to grow over 40% in 2026 and potentially fivefold over time. Natera's competitive advantages in clinical evidence, commercial infrastructure, and a diversified multi-segment strategy, including noninvasive pren", "sentiment_score": 0.459435, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "alpha_vantage", "title": "NTRA Initiated Coverage On by William Blair -- Rating Outperform", "url": "https://www.gurufocus.com/news/8792438/ntra-initiated-coverage-on-by-william-blair-rating-outperform", "date": "2026-04-14", "summary": "William Blair analyst Andrew Brackmann initiated coverage on Natera (NTRA) with an 'Outperform' rating, signaling a positive outlook for the genetic testing company. Despite this, GuruFocus assesses NTRA as approximately 14.1% overvalued, with significant insider selling amounting to $124.1 million in the last three months. The company boasts a high GF Score™ of 85/100, driven by strong growth potential, though its profitability ranks lower.", "sentiment_score": 0.29959, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Natera Inc stock (US6323071042): Is cell-free DNA testing strong enough to unlock sustained growth?", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/natera-inc-stock-us6323071042-is-cell-free-dna-testing-strong-enough-to/69145512", "date": "2026-04-14", "summary": "Natera Inc. is a leader in cell-free DNA testing, offering diagnostics for cancer monitoring (Signatera) and prenatal screening (Panorama), primarily targeting the U.S. and English-speaking markets. The company leverages proprietary algorithms and R&D to drive accuracy and scalability, positioning itself as a strong player in the high-growth diagnostics sector. Despite risks like reimbursement volatility and intense competition, analysts view the stock positively due to robust test volume growth", "sentiment_score": 0.414853, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.71, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "Lymphoma patients on Allogene therapy saw ctDNA drop 97.7% by Day 45", "url": "https://www.stocktitan.net/news/NTRA/natera-highlights-positive-interim-futility-analysis-from-allogene-reiwpxdxw5s5.html", "date": "2026-04-14", "summary": "Natera highlighted interim futility analysis results from Allogene Therapeutics’ ALPHA3 trial for cema-cel, an investigational CAR T therapy for large B-cell lymphoma. The study showed that 58.3% of MRD-positive patients treated with cema-cel achieved MRD clearance, and their circulating tumor DNA levels dropped by a median of 97.7% compared to an increase in the observation arm. These findings suggest that cema-cel could prevent or delay clinical relapse in LBCL patients with molecular residual", "sentiment_score": 0.011715, "sentiment_label": "Neutral", "relevance_score": 0.340071, "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "William Blair initiates Natera stock with Outperform on growth outlook", "url": "https://m.investing.com/news/analyst-ratings/william-blair-initiates-natera-stock-with-outperform-on-growth-outlook-93CH-4611328?ampMode=1", "date": "2026-04-13", "summary": "William Blair has initiated coverage on Natera Inc. (NASDAQ:NTRA) with an Outperform rating, citing the company's leading positions in diagnostic markets and its diversified, growing portfolio. Despite trading at a premium compared to peers, William Blair believes Natera's market leadership and first-mover advantage justify the valuation, expecting significant earnings power even though the company is not yet profitable. The article also mentions recent court decisions favoring Natera, board exp", "sentiment_score": 0.425517, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.582, "confidence": 0.58 } }, { "source": "alpha_vantage", "title": "Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma", "url": "https://www.businesswire.com/news/home/20260413928881/en/Natera-Highlights-Positive-Interim-Futility-Analysis-from-Allogene-Therapeutics-MRD-Guided-ALPHA3-Trial-in-Large-B-Cell-Lymphoma", "date": "2026-04-13", "summary": "Natera announced positive interim futility analysis from Allogene Therapeutics’ ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL). The trial uses Natera's CLARITY™ MRD assay to identify high-risk patients. The analysis showed that 58.3% of MRD-positive patients treated with cema-cel achieved MRD clearance, suggesting it may prevent or delay clinical relapse.", "sentiment_score": 0.426189, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "alpha_vantage", "title": "Court orders 30% ongoing royalty for Natera in patent dispute", "url": "https://www.msn.com/en-us/health/medical/court-orders-30-ongoing-royalty-for-natera-in-patent-dispute/ar-AA20vSFn", "date": "2026-04-12", "summary": "A court has ordered a 30% ongoing royalty payment to Natera stemming from a patent dispute. This decision implies a significant win for Natera regarding its intellectual property rights. The royalty structure suggests continued financial benefits for Natera from the disputed technology.", "sentiment_score": 0.814417, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Natera Claims Top Trading Volume as Legal Victory Sparks $550 Million Surge Amid Price Drop", "url": "https://www.bitget.com/amp/news/detail/12560605357844", "date": "2026-04-11", "summary": "Natera Inc. (NTRA) experienced a significant $550 million surge in trading volume despite a 4.91% price drop, following a favorable legal ruling that increased royalty rates from 10% to 30% on infringing MRD-related product sales. This legal victory strengthens Natera's intellectual property in the oncology diagnostics market but was met with profit-taking or reassessment by investors. The market is now keenly watching how these legal developments will translate into financial results in upcomin", "sentiment_score": 0.137245, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "alpha_vantage", "title": "NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA)", "url": "https://www.chartmill.com/stock/quote/NTRA/profile", "date": "2026-04-10", "summary": "This article provides a detailed overview of Natera Inc. (NTRA) stock, including its current price, performance metrics, and key statistics like market capitalization and EPS. It also covers technical and fundamental analysis ratings from ChartMill, recent earnings, future forecasts, and company profile information. Investors can find insights into the company's financial health, ownership structure, and comparisons with competitors in the biotechnology sector.", "sentiment_score": 0.11046, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera awarded 30% ongoing royalty in MRD patent litigation", "url": "https://www.msn.com/en-us/money/companies/natera-awarded-30-ongoing-royalty-in-mrd-patent-litigation/ar-AA20uqCc?uxmode=ruby&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-04-10", "summary": "Natera has been awarded a 30% ongoing royalty in its patent litigation concerning minimal residual disease (MRD) testing. This outcome follows an earlier court ruling that found certain of Natera's intellectual property was infringed. The royalty likely applies to future sales or activities related to the infringed patents.", "sentiment_score": 0.84249, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "alpha_vantage", "title": "Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA)", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/court-win-on-mrd-patents-and-royalties-might-change-the-case", "date": "2026-04-10", "summary": "Natera recently secured a favorable court ruling, upholding the validity of its three MRD patents and granting a 30% royalty on infringing product sales. This decision bolsters Natera's intellectual property in molecular residual disease testing, potentially enhancing its market position and revenue outlook. While strengthening Natera's investment narrative, the article notes that investors should still consider risks such as high cash burn and challenges in clinical trials and reimbursement.", "sentiment_score": 0.410353, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "alpha_vantage", "title": "Director Eric H. Rubin joins Natera (NTRA) insider roster with Form 3 filing", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-3-natera-inc-initial-statement-of-beneficial-ownership-d9ef1efdbc22.html", "date": "2026-04-10", "summary": "Natera, Inc. (NTRA) director Eric H. Rubin has filed an initial Form 3 with the SEC, formally establishing his status as an insider. This filing indicates that Rubin is a director of the company and brings him under insider reporting requirements, though it does not report any beneficial ownership of securities or trading activity. The Form 3 serves as an initial statement of beneficial ownership, providing transparency on his new insider role.", "sentiment_score": 0.032919, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle", "url": "https://www.benzinga.com/markets/equities/26/04/51727487/judge-hands-natera-30-ongoing-royalty-in-mrd-patent-battle", "date": "2026-04-09", "summary": "A Delaware court has awarded Natera a 30% ongoing royalty on post-injunction revenues related to its MRD patents, building on a previous 20.5% royalty for pre-injunction sales. The court also upheld the validity and infringement findings of Natera's patents against ArcherDx and Invitae, strengthening Natera's intellectual property portfolio. Natera's shares saw a slight increase in premarket trading following the announcement, and the company is expected to release its next financial update in M", "sentiment_score": 0.633458, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Natera Says Court Orders 30% Royalties From ArcherDx, Invitae on Post-Injunction Sales", "url": "https://www.marketscreener.com/news/natera-says-court-orders-30-royalties-from-archerdx-invitae-on-post-injunction-sales-ce7e50dbd189f726", "date": "2026-04-09", "summary": "A court has ordered ArcherDx and Invitae to pay a 30% royalty to Natera for post-injunction sales. This decision follows a patent dispute and is expected to impact the financial performance of the involved diagnostic companies. Natera, a diagnostics company focusing on women's health, oncology, and organ health, will receive these royalties.", "sentiment_score": 0.419329, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera wins 30% ongoing royalty in patent case against Invitae By Investing.com", "url": "https://in.investing.com/news/company-news/natera-wins-30-ongoing-royalty-in-patent-case-against-invitae-93CH-5329628", "date": "2026-04-09", "summary": "Natera Inc. has won a court decision granting it a 30% ongoing royalty on post-injunction revenues from certain minimal residual disease-related product sales by ArcherDx and Invitae. This ruling follows an earlier injunction and upholds the validity of Natera's MRD patents. The company, trading at $210.83 with a market capitalization of $29.88 billion, has seen its stock valuation positively influenced, with analysts revising earnings upwards despite an InvestingPro analysis suggesting it is cu", "sentiment_score": 0.457022, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) chair exercises options, uses shares for taxes", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-69aa6881ce05.html", "date": "2026-04-09", "summary": "Matthew Rabinowitz, Executive Chairman of Natera (NASDAQ: NTRA), exercised stock options to acquire 58,292 shares at $9.59 each and subsequently had 27,610 shares withheld at $204.87 for tax obligations. Following these transactions, Rabinowitz directly holds 2,383,162 shares and indirectly holds 5,000 shares through his spouse. The filing also details key figures like exercise price, tax-withholding price, and his holdings after the transactions.", "sentiment_score": 0.005434, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "NTRA Financials: Revenue Breakdown, Margins & Competitor Comparison", "url": "https://intellectia.ai/en/stock/NTRA/financials", "date": "2026-04-08", "summary": "This article provides a financial analysis of Natera Inc (NTRA), detailing its revenue breakdown, profit margins, and a comparison with competitors. Natera primarily generates revenue from insurance carriers, holding a significant market share with a $29.66 billion market capitalization. It highlights the company's gross margin, operating margin, and net margin, alongside its Return on Equity, and benchmarks its gross margin against industry rivals IQV and UTHR.", "sentiment_score": 0.148492, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera Inc. (NTRA): Upside Potential Pulls Billionaire Stan Druckenmiller", "url": "https://www.insidermonkey.com/blog/natera-inc-ntra-upside-potential-pulls-billionaire-stan-druckenmiller-1733871/?amp=1", "date": "2026-04-08", "summary": "Billionaire Stan Druckenmiller's Duquesne Capital holds a significant stake in Natera, Inc. (NTRA), increasing its position in the company which is recognized for its molecular residual disease test, Signatera. Natera's recent achievement of positive cash inflow in 2025 has shifted the narrative among institutional investors, mitigating concerns about cash burn and potential dilution risks. The article highlights the strong growth of Signatera and Natera's growing integration into clinical guide", "sentiment_score": 0.48074, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "url": "https://www.businesswire.com/news/home/20260407837545/en/20-Abstracts-at-AACR-Highlight-Scale-Innovation-and-Clinical-Impact-of-Nateras-Oncology-Platform", "date": "2026-04-08", "summary": "Natera, Inc. announced that 20 abstracts, including two oral presentations, featuring data generated using its technologies will be presented at the 2026 AACR Annual Meeting. These presentations highlight advances in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and the ongoing expansion of their molecular residual disease (MRD) and other capabilities. The research demonstrates Natera's innovative approaches to provide more precise and data-driven solutions in cancer care.", "sentiment_score": 0.499111, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.812, "confidence": 0.81 } }, { "source": "alpha_vantage", "title": "Citi Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $300", "url": "https://www.moomoo.com/news/post/67968518/citi-maintains-natera-ntraus-with-buy-rating-maintains-target-price", "date": "2026-04-08", "summary": "Citi has reiterated its Buy rating for Natera (NTRA.US) and maintained a target price of $300. This continued endorsement suggests the firm sees strong potential for the company's performance, indicating a positive outlook on its valuation and business prospects.", "sentiment_score": 0.447552, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "url": "https://www.biospace.com/press-releases/20-abstracts-at-aacr-highlight-scale-innovation-and-clinical-impact-of-nateras-oncology-platform", "date": "2026-04-07", "summary": "Natera, Inc. announced that 20 abstracts, including two oral presentations, featuring data from its oncology technologies will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. These presentations highlight the scale, innovation, and clinical impact of Natera's oncology platform, including advancements in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and expansion of molecular residual disease (MRD) capabilities. Key research areas inc", "sentiment_score": 0.420341, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.812, "confidence": 0.81 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) Gets 90-Day Catalyst Watch from Citi and Maintains Buy Rating", "url": "https://www.gurufocus.com/news/8777278/natera-ntra-gets-90day-catalyst-watch-from-citi-and-maintains-buy-rating?mobile=true", "date": "2026-04-07", "summary": "Citi has placed Natera (NTRA) on a \"90-day catalyst watch\" and reaffirmed its Buy rating with a $300 price target, anticipating strong financial momentum despite a recent stock pullback. Natera, a diagnostic and research company, shows robust revenue growth and a strong balance sheet but faces challenges in profitability and has high institutional ownership alongside insider selling. The company's performance, particularly upcoming earnings, will be key to its future trajectory, requiring invest", "sentiment_score": 0.424255, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "56,665 Shares in Natera, Inc. $NTRA Purchased by Robinhood Asset Management LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-56665-shares-in-natera-inc-ntra-purchased-by-robinhood-asset-management-llc-2026-04-07/", "date": "2026-04-07", "summary": "Robinhood Asset Management LLC recently acquired 56,665 shares of Natera, Inc. (NTRA) in the fourth quarter, a stake valued at approximately $12.98 million, making it their 23rd largest holding. While Natera exceeded Q4 earnings and revenue estimates, it remains unprofitable, and insiders have sold a significant number of shares recently. Despite high institutional ownership, analysts have a \"Moderate Buy\" consensus rating with an average target price of $253.47.", "sentiment_score": 0.18839, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Evercore Maintains Natera(NTRA.US) With Buy Rating, Cuts Target Price to $250", "url": "https://www.moomoo.com/news/post/67925664/evercore-maintains-natera-ntraus-with-buy-rating-cuts-target-price", "date": "2026-04-06", "summary": "Evercore has reiterated its Buy rating on Natera (NTRA.US) stock while simultaneously lowering its price target to $250. This adjustment indicates a continued positive outlook on the company despite potential short-term headwinds or revised growth expectations, reflected in the reduced target price. Investors will likely be watching Natera's performance closely in light of Evercore's maintained confidence but recalibrated valuation.", "sentiment_score": 0.000385, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera president sells $606,899 in NTRA stock", "url": "https://www.investing.com/news/insider-trading-news/natera-president-sells-606899-in-ntra-stock-93CH-4597490", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 3,000 shares of NTRA stock for approximately $606,899 on April 1, 2026. These sales, executed under a pre-arranged trading plan, occurred at prices ranging from $201.32 to $203.31 per share. This insider transaction comes as Natera stock trades above its InvestingPro Fair Value, suggesting potential overvaluation, though the company recently announced advancements in medical testing and an expanded board.", "sentiment_score": 0.066439, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/natera-nasdaqntra-insider-solomon-moshkevich-sells-3000-shares-of-stock-2026-04-03/", "date": "2026-04-04", "summary": "Natera insider Solomon Moshkevich recently sold 3,000 shares of the company's stock for over $600,000, reducing his stake by 1.99%. This transaction is part of a pattern of ongoing insider disposals by Moshkevich, who has made several other significant sales since January. Despite these insider sales, Natera recently exceeded quarterly EPS and revenue estimates and holds a \"Moderate Buy\" consensus analyst rating with a target price of $253.47.", "sentiment_score": -0.209927, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.95693, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera president sells $606,899 in NTRA stock", "url": "https://m.investing.com/news/insider-trading-news/natera-president-sells-606899-in-ntra-stock-93CH-4597490?ampMode=1", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), sold 3,000 shares of company stock for approximately $606,899 on April 1, 2026. These sales were executed under a pre-arranged trading plan, and Moshkevich still directly owns 147,882 shares. The article also touches on recent company developments, including new genetic tests and board expansion, and an adjusted price target by Morgan Stanley.", "sentiment_score": 0.142045, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera SEC. sold $1.7m in NTRA stock", "url": "https://www.investing.com/news/insider-trading-news/natera-sec-sold-17m-in-ntra-stock-93CH-4597491", "date": "2026-04-04", "summary": "Daniel Rabinowitz, SEC. and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), sold 8,400 shares of common stock totaling $1.7 million on April 1, 2026. This insider sale followed a 55% surge in Natera's stock over the past year, placing it among InvestingPro's most overvalued companies. The company has recently launched new genomics tests and seen a price target adjustment from Morgan Stanley.", "sentiment_score": 0.087871, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) president sells 3,000 shares under Rule 10b5-1 plan", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-7cfdbe66df68.html", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), sold 3,000 shares of common stock on April 1, 2026, through an open-market transaction. These sales were pre-arranged under a Rule 10b5-1 trading plan adopted on November 26, 2024. Following these transactions, Moshkevich directly holds 147,882 shares of Natera.", "sentiment_score": -0.292677, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) legal chief sells 8,400 shares in preset 10b5-1 plan", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-0e25ff27fe5c.html", "date": "2026-04-04", "summary": "Natera's Secretary and Chief Legal Officer, Daniel Rabinowitz, sold 8,400 shares of the company's common stock on April 1, 2026. The sales were conducted through a pre-arranged Rule 10b5-1 trading plan at weighted average prices between $200.47 and $205.50 per share. Following these transactions, Rabinowitz still holds 224,885 shares of Natera common stock.", "sentiment_score": 0.014188, "sentiment_label": "Neutral", "relevance_score": 0.334272, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Natera SEC. sold $1.7m in NTRA stock", "url": "https://m.investing.com/news/insider-trading-news/natera-sec-sold-17m-in-ntra-stock-93CH-4597491?ampMode=1", "date": "2026-04-04", "summary": "Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc. (NASDAQ:NTRA), sold 8,400 shares of common stock for $1.7 million on April 1, 2026, through a Rule 10b5-1 trading plan. This sale occurred as Natera's stock surged 55% over the past year. In other news, Natera launched Zenith genomics and its Signatera test showed promising results in cancer studies.", "sentiment_score": -0.214249, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) chair exercises 41,708 options, now holds 2.35M shares", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-2cb7102ee209.html", "date": "2026-04-02", "summary": "Matthew Rabinowitz, Executive Chairman of Natera (NTRA), exercised 41,708 stock options at a strike price of $9.59 per share. This transaction increased his direct holdings to 2,352,480 shares of Natera Common Stock, with an additional 58,292 stock options and 5,000 indirect shares through his spouse. The filing confirms no shares were sold and the options were fully exercisable.", "sentiment_score": 0.014708, "sentiment_label": "Neutral", "relevance_score": 0.33173, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera Expands Board, Appoints Eric Rubin as Director", "url": "https://www.tipranks.com/news/company-announcements/natera-expands-board-appoints-eric-rubin-as-director", "date": "2026-04-01", "summary": "Natera has expanded its Board of Directors from ten to eleven members, appointing Eric Rubin as an independent Class I director effective March 26, 2026. Dr. Rubin will also join the Nominating, Corporate Governance and Compliance Committee and will receive standard director compensation. This move emphasizes Natera's commitment to independent oversight and regulatory compliance, with Dr. Rubin having no related-party ties to the company.", "sentiment_score": 0.251555, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Eric Rubin appointed to Natera board as Class I director", "url": "https://www.tradingview.com/news/tradingview:cf61fa6d2a1b1:0-eric-rubin-appointed-to-natera-board-as-class-i-director/", "date": "2026-04-01", "summary": "Natera has appointed Eric Rubin to its Board of Directors as a Class I director, effective March 26, 2026. This appointment increased the board's size from ten to eleven members, with Rubin also joining the Nominating, Corporate Governance and Compliance Committee. He will receive standard cash and equity compensation for non-employee directors, with his initial equity award vesting over three years.", "sentiment_score": 0.39746, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Eric Rubin joins Natera (NASDAQ: NTRA) board as independent director", "url": "https://www.stocktitan.net/sec-filings/NTRA/8-k-natera-inc-reports-material-event-10e242e4f351.html", "date": "2026-04-01", "summary": "Natera, Inc. has expanded its Board of Directors to eleven members by appointing Eric Rubin as a Class I independent director, effective March 26, 2026. Dr. Rubin will serve on the Nominating, Corporate Governance and Compliance Committee and will receive standard cash and equity compensation, with his initial equity award vesting in three equal installments. An Indemnification Agreement has also been put in place for his service to the company.", "sentiment_score": 0.232693, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "J. Safra Sarasin Holding AG Makes New Investment in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-j-safra-sarasin-holding-ag-makes-new-investment-in-natera-inc-ntra-2026-04-01/", "date": "2026-04-01", "summary": "J. Safra Sarasin Holding AG recently acquired a new stake of 12,331 shares in Natera, Inc. (NASDAQ:NTRA), valued at approximately $2.83 million, during the fourth quarter. This move aligns with other institutional investors, contributing to Natera's 99.90% institutional ownership. Despite beating Q4 earnings estimates with $0.35 EPS and $665.5 million in revenue, the company remains unprofitable with significant insider selling recorded, while analysts hold a \"Moderate Buy\" consensus.", "sentiment_score": 0.218938, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Signatera Data in Older Breast Cancer Patients Could Be A Game Changer For Natera (NTRA)", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/signatera-data-in-older-breast-cancer-patients-could-be-a-ga", "date": "2026-04-01", "summary": "Natera's Signatera molecular residual disease test has shown promising results in a new study, allowing older women with early-stage ER+/HER2- breast cancer to opt for primary endocrine therapy over surgery. This development could reshape Natera's investment narrative by reinforcing Signatera's clinical utility and potentially influencing future reimbursement decisions for various oncology indications. Despite optimistic forecasts, analysts remain cautious about the company's path to profitabili", "sentiment_score": 0.438633, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Allspring Global Investments Holdings LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-allspring-global-investments-holdings-llc-2026-04-01/", "date": "2026-04-01", "summary": "Allspring Global Investments Holdings LLC significantly reduced its stake in Natera, Inc. (NTRA) by 4.4% in the fourth quarter, selling 20,896 shares and retaining 454,498 shares. This comes amidst heavy insider selling, including transactions by CEO Steven Chapman and another insider, totaling over $74.1 million in the last quarter, though insiders still hold 5.63% of the stock. Despite this, institutional investors collectively own 99.90% of Natera's stock, and the company reported an EPS beat", "sentiment_score": 0.055517, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery", "url": "https://www.benzinga.com/news/health-care/26/03/51576065/nateras-signatera-data-suggests-select-breast-cancer-patients-could-skip-surgery", "date": "2026-03-31", "summary": "Natera's Signatera molecular residual disease (MRD) test has shown promising results, indicating that select breast cancer patients could potentially avoid surgery. A study published in Clinical Cancer Research demonstrated Signatera's ability to identify older women with early-stage ER+/HER2- breast cancer who can be effectively managed with primary endocrine therapy. The study highlights Signatera's strong predictive accuracy and early-detection capabilities, supporting its utility for non-sur", "sentiment_score": 0.039618, "sentiment_label": "Neutral", "relevance_score": 0.33015, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Avoiding Lag: Real-Time Signals in (NTRA) Movement", "url": "https://news.stocktradersdaily.com/news_release/12/Avoiding_Lag:_Real-Time_Signals_in_NTRA_Movement_033126033202_1774985522.html", "date": "2026-03-31", "summary": "This article provides a detailed analysis of Natera Inc. (NASDAQ: NTRA) movement, highlighting weak near-term sentiment despite long-term strength. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes a strong risk-reward setup, real-time signals, and multi-timeframe insights for traders.", "sentiment_score": 0.198007, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.586, "confidence": 0.59 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Zevenbergen Capital Investments LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-zevenbergen-capital-investments-llc-2026-03-31/", "date": "2026-03-31", "summary": "Zevenbergen Capital Investments LLC has reduced its stake in Natera, Inc. by 18% in the fourth quarter, selling 70,994 shares, although the stock still constitutes 1.6% of its portfolio. Despite this, other institutional investors have shown increased interest, while significant insider selling, including by the CFO and CEO, has occurred. Analysts maintain a \"Moderate Buy\" consensus for Natera, with an average price target of $253.47, following strong quarterly results that beat expectations.", "sentiment_score": 0.033602, "sentiment_label": "Neutral", "relevance_score": 0.335162, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "42006433", "title": "Stability of integrated polygenic and clinical coronary artery disease risk prediction.", "authors": "Ratman D et al.", "journal": "American journal of preventive cardiology", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/42006433/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "42002707", "title": "ASO Author Reflections: Potential of Circulating Tumor DNA in Stratifying Patients with Localized pMMR Colon Cancer to Neoadjuvant Therapy.", "authors": "Smith HG et al.", "journal": "Annals of surgical oncology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/42002707/", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "pubmed", "pmid": "42001368", "title": "Primitive neuronal component is a frequent finding among IDH-mutant astrocytomas with RB1 alterations.", "authors": "Slocum CC et al.", "journal": "Acta neuropathologica", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/42001368/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "42000949", "title": "Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies.", "authors": "Bevilacqua R et al.", "journal": "NPJ precision oncology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/42000949/", "sentiment": { "label": "negative", "score": -0.694, "confidence": 0.69 } }, { "source": "pubmed", "pmid": "42000377", "title": "Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends.", "authors": "Levin G et al.", "journal": "Gynecologic oncology", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/42000377/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41997767", "title": "Corrigendum to \"Improving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants\" [American Journal of Transplantation Volume 26, Issue 1, January 2026, Pages 117-130].", "authors": "Hidalgo LG et al.", "journal": "American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41997767/", "sentiment": { "label": "negative", "score": -0.178, "confidence": 0.18 } }, { "source": "pubmed", "pmid": "41997214", "title": "Phenotypic discordance in monozygotic twins with a CDH2 variant.", "authors": "Hansman L et al.", "journal": "European journal of medical genetics", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41997214/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41997125", "title": "Targeting genomic instability in cancer.", "authors": "Yap TA et al.", "journal": "Cell", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41997125/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41995460", "title": "Critical Questions in Genomic Diagnostics for Veterinary Oncology: What We Need to Know.", "authors": "Sakthikumar S et al.", "journal": "Veterinary and comparative oncology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41995460/", "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "pubmed", "pmid": "41994456", "title": "Lung allograft injury improves after gastroesophageal reflux surgery by donor-derived cell-free DNA kinetics.", "authors": "Sultan S et al.", "journal": "Frontiers in medicine", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41994456/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41991755", "title": "In vivo exposure to CXCL12-high CAFs and chronic CXCL12 stimulation in vitro is sufficient to enhance metastasis of ER-positive breast cancer.", "authors": "Miller PC et al.", "journal": "Breast cancer research and treatment", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41991755/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41991549", "title": "Acute circulating tumor DNA dynamics during and after systemic therapy initiation for advanced triple-negative breast cancer.", "authors": "To B et al.", "journal": "NPJ breast cancer", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41991549/", "sentiment": { "label": "negative", "score": -0.599, "confidence": 0.6 } }, { "source": "pubmed", "pmid": "41991264", "title": "Indocyanine green fluorescence for intraoperative detection of liver tumours in minimally invasive surgery: protocol for the LIVERGREEN phase IV multicentre clinical trial.", "authors": "Huerta M et al.", "journal": "BMJ open", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41991264/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41991095", "title": "Utility of donor-derived cell-free DNA testing after lung transplantation in the precision medicine era.", "authors": "Keller BC et al.", "journal": "The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41991095/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41990751", "title": "Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition.", "authors": "Reyes J et al.", "journal": "Cell", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41990751/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41990718", "title": "Covalently bound Eosin Y on chitosan as a removable photosensitizer for ranitidine degradation.", "authors": "Sacchetto JL et al.", "journal": "Chemosphere", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41990718/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41990605", "title": "Integrin beta-6: Its emerging role as a therapeutic target in solid tumors.", "authors": "Sanborn RE et al.", "journal": "Cancer treatment reviews", "date": "2026 Apr 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41990605/", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41988139", "title": "Immune checkpoint inhibitors in resectable non-small cell lung cancer: recent successes and ongoing challenges.", "authors": "Abodunrin FO et al.", "journal": "Frontiers in oncology", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41988139/", "sentiment": { "label": "negative", "score": -0.077, "confidence": 0.08 } }, { "source": "pubmed", "pmid": "41988121", "title": "Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model.", "authors": "Lentz RW et al.", "journal": "Frontiers in oncology", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41988121/", "sentiment": { "label": "negative", "score": -0.691, "confidence": 0.69 } }, { "source": "pubmed", "pmid": "41981779", "title": "Hepatic-Differentiated Subpopulation in Clear Cell Renal Cell Carcinoma: A Multi-Omics Analysis of Tumors With Lymphovascular Invasion.", "authors": "Yajima S et al.", "journal": "Cancer medicine", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41981779/", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41981308", "title": "Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.", "authors": "Mahalingam D et al.", "journal": "Nature medicine", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41981308/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41980929", "title": "Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.", "authors": "Hansen DK et al.", "journal": "Blood cancer journal", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41980929/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41979882", "title": "Oncology Clinicians' Attitudes on Hormonal Therapy After Chemoradiotherapy for Cervical Cancer.", "authors": "Levy MS et al.", "journal": "JAMA network open", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41979882/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41974150", "title": "Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.", "authors": "Colombo N et al.", "journal": "Lancet (London, England)", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41974150/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41974149", "title": "Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.", "authors": "Lorusso D et al.", "journal": "Lancet (London, England)", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41974149/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41972229", "title": "Donor-derived Cell-free DNA for Detection of Rejection After Pancreas Transplantation.", "authors": "Matar AJ et al.", "journal": "Transplantation direct", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41972229/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41968872", "title": "Absolute and Fractional Donor-Derived Cell-Free DNA in the Follow-Up of Kidney Allograft Rejection.", "authors": "Petr V et al.", "journal": "HLA", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41968872/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41963611", "title": "Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.", "authors": "Venturini J et al.", "journal": "NPJ precision oncology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41963611/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41962310", "title": "New prognostic and predictive scoring systems for colorectal cancer liver metastases.", "authors": "Salvà F et al.", "journal": "ESMO open", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41962310/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41956543", "title": "HosTIL territory: mapping the landscape of toxicity in TIL therapy.", "authors": "Woodford R et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41956543/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41955548", "title": "Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience.", "authors": "Abidoye O et al.", "journal": "JCO precision oncology", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41955548/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41954938", "title": "Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.", "authors": "Leone JP et al.", "journal": "JAMA network open", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41954938/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41954928", "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.", "authors": "Gupta S et al.", "journal": "JAMA", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41954928/", "sentiment": { "label": "negative", "score": -0.758, "confidence": 0.76 } }, { "source": "pubmed", "pmid": "41953531", "title": "Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary.", "authors": "Sullivan MW et al.", "journal": "Gynecologic oncology reports", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41953531/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41953135", "title": "Concordance between genome-wide cfDNA screening and diagnostic test results for large copy-number variants: a multi-site study from the Global Expanded NIPT Consortium.", "authors": "Soster E et al.", "journal": "Frontiers in genetics", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41953135/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41950572", "title": "From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.", "authors": "Ambrosini M et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Apr 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41950572/", "sentiment": { "label": "negative", "score": -0.34, "confidence": 0.34 } }, { "source": "pubmed", "pmid": "41945184", "title": "The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancer.", "authors": "Fadelu TA et al.", "journal": "Breast cancer research and treatment", "date": "2026 Apr 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41945184/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41940628", "title": "SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.", "authors": "Peters S et al.", "journal": "Future oncology (London, England)", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41940628/", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41939727", "title": "Remote digital intervention targeting heart failure medical therapy: a randomized controlled trial.", "authors": "DeVore AD et al.", "journal": "Lancet regional health. Americas", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41939727/", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "pubmed", "pmid": "41933595", "title": "Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.", "authors": "Miller DG et al.", "journal": "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933595/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "pubmed", "pmid": "41931740", "title": "Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy-Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors.", "authors": "Bogdani C et al.", "journal": "JCO precision oncology", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41931740/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41926089", "title": "Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.", "authors": "Park CS et al.", "journal": "JAMA oncology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41926089/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41925239", "title": "How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study.", "authors": "Gupta S et al.", "journal": "Future oncology (London, England)", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41925239/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41924551", "title": "Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.", "authors": "Eslinger C et al.", "journal": "Drug design, development and therapy", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41924551/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41922555", "title": "A Mobile Exhibition to Advance Cancer Prevention Awareness: A Cross-Sectional Evaluation Using the RE-AIM Framework.", "authors": "Fey T et al.", "journal": "Journal of cancer education : the official journal of the American Association for Cancer Education", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41922555/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41919756", "title": "How genetic counselors in North America describe their professional identity.", "authors": "Schwartz L et al.", "journal": "Journal of genetic counseling", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41919756/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41917040", "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "authors": "Liang J et al.", "journal": "Nature communications", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41917040/", "sentiment": { "label": "negative", "score": -1.0, "confidence": 1.0 } }, { "source": "pubmed", "pmid": "41912809", "title": "Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.", "authors": "Wainberg ZA et al.", "journal": "Nature medicine", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41912809/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41910021", "title": "A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.", "authors": "Johnson ML et al.", "journal": "Future oncology (London, England)", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41910021/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41908612", "title": "Three People With Recurrent Nephrolithiasis and Heterozygous ABCC6 Mutations.", "authors": "Farrell D et al.", "journal": "Kidney medicine", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41908612/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } } ] } }